Most of menopausal menopausal symptoms in women are associated with inadequate estrogen production. Estrogen refers to steroid hormones and is produced by the ovaries. It stimulates the development of women's reproductive organs, the formation of secondary female sex characteristics, promotes timely rejection of the endometrium and regular monthly bleeding.
After menopause, a decrease in the level of estrogen in many women causes vasomotor and thermoregulatory instability ("hot flushes" of the blood to the skin of the face), sleep disorders, partial atrophy of the urogenital system, osteoporosis.
The active substance of the preparation Saghenit influences the functioning of the endocrinological network, which connects the hypothalamus, pituitary and ovaries and controls the cyclic changes in the ovaries and endometrium (the inner mucosa of the uterus body).
Sagenite reduces the gonadotropic function of the pituitary gland, that is, the production of gonadotropic hormones (follicle-stimulating, luteotropic and luteinizing), which affect the function of the ovary woman. In addition, the substance sygetin has an effect on the hypothalamic center, whose functions include maintaining the optimal level of metabolism, regulating the body's temperature balance, the work of the cardiovascular, digestive, excretory, respiratory systems and endocrine glands.
The manufacturer of the drug Saghenit indicates that this drug does not have an estrogenic effect on the target organs, that is, does not fill the deficiency of endogenous estrogens. At the same time, Sagenite increases uterine contractions and increases placental blood flow - blood circulation in the mother-placenta-fetus system (during pregnancy).
It should be noted that the analog preparation Sigetin (with the same active substance) is recommended as a stimulant of labor.